TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22354999

Group type: EXPERIMENTAL
Intervention: Guided self-instruction for CFS delivered by nurses
Number of subjects: 123

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Guided self-instruction for CFS in subgroup with physical disabilities (SF-36 physical functioning ≤70)
Number of subjects: 123
Study: 19267956

Group type: EXPERIMENTAL
Intervention: left PET-guided rTMS (n = 9)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: standard rTMS (n = 18)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: stimulation over dorsolateral prefrontal cortex (BA 9-46, n = 15)
Number of subjects: 48

Group type: COMPARATOR
Intervention: sham rTMS (n = 14)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: right PET-guided rTMS
Number of subjects: 48
Study: 17666597

Group type: EXPERIMENTAL
Intervention: IVIG 2 g/kg/wk (group A)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg/wk plus prednisone 0.5 mg/kg/d (group B)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 73
Study: 16146257

Group type: EXPERIMENTAL
Intervention: TEA with 0.2% ropivacaine and ipsilateral brachial plexus block (BPB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 50
Study: 11823672

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL (100 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9935096

Group type: EXPERIMENTAL
Intervention: LPA therapy at 20 J/cm2, double pulsed at a repetition rate of one Hz
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LPA therapy at 20 J/cm2, single pulsed with a pulse duration of 5 msec followed by 23.4% hypertonic saline sclerotherapy
Number of subjects: 28
Study: 8785378

Group type: EXPERIMENTAL
Intervention: 10 mg selegiline tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg selegiline solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of both dosage forms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (tablet and solution)
Number of subjects: 0
Study: 2222626

Group type: EXPERIMENTAL
Intervention: New technique (n = 46)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Shirodkar operation (n = 44)
Number of subjects: 90
Study: 16203

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 67
Study: 30927150

Group type: EXPERIMENTAL
Intervention: BioRoot RCS
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Totalfill BC
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 66

Group type: COMPARATOR
Intervention: No sealer (Control)
Number of subjects: 66
Study: 27999018

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (0.3‐0.6 mg/kg twice daily) with ART (tenofovir, emtricitabine and lopinavir/ritonavir) for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: ART alone (tenofovir, emtricitabine and lopinavir/ritonavir)
Number of subjects: 20
Study: 26310984

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 23263720

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin (135‐180 µg subcutaneously/week and 800‐1200 mg/day orally)
Number of subjects: 168

Group type: COMPARATOR
Intervention: interferon alfa‐2b plus ribavirin (300‐500 million units, once every other day and 800‐1200 mg/day)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: RVR (Rapid Virological Response)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: No RVR
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: EVR (Early Virological Response)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: No EVR
Number of subjects: 168
Study: 20456906

Group type: COMPARATOR
Intervention: E alone (epinephrine)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: E+V (epinephrine plus vasopressin)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: E+V+N (epinephrine plus vasopressin plus nitroglycerin)
Number of subjects: 44
Study: 19168868

Group type: EXPERIMENTAL
Intervention: QuBE score
Number of subjects: 790
Study: 16904092

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 22

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 22
Study: 15146409

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg subcutaneously every week
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study: 14723388

Group type: EXPERIMENTAL
Intervention: ECG criteria (Sokolow‐Lyon and Cornell voltage with repolarisation criteria)
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Cornell criteria
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: ECG
Number of subjects: 890
Study: 10467196

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily, n = 14)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 21
Study: 7601400

Group type: EXPERIMENTAL
Intervention: Bolus somatostatin (250 micrograms injection followed by 250 micrograms/h infusion)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous somatostatin (250 micrograms/h infusion)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous somatostatin (500 micrograms/h infusion)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2210972

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg at 12-hour intervals (30 subjects)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg at 12-hour intervals (24 subjects)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg at 12-hour intervals for three days (23 subjects with uncomplicated UTI)
Number of subjects: 77
Study: 356181

Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 91

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 91
Study: 31331065

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed whey formula with 1.8 g protein/100 kcal (pHF1.8)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed whey formula with 2.27 g protein/100 kcal (pHF2.27)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed whey formula with 2.0 g protein/100 kcal (pHF2.0)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: All groups (pHF1.8, pHF2.0, pHF2.27)
Number of subjects: 207
Study: 28698351

Group type: EXPERIMENTAL
Intervention: 1 mg/kg intranasal ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volume-matched intranasal normal saline (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard analgesic therapy (for all participants)
Number of subjects: 0
Study: 23807349

Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol fixed combination therapy (FCBT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol fixed combination therapy (FCDT)
Number of subjects: 60
Study: 23725301

Group type: EXPERIMENTAL
Intervention: Dissolved oxygen dressing (OxygeneSys™‐Continuous)
Number of subjects: 50
Study: 21542774

Group type: EXPERIMENTAL
Intervention: One-stage tract dilation (group 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gradual tract dilation (group 1)
Number of subjects: 48
Study: 19523908

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (0.1 ml of trivalent inactivated influenza vaccine, 3 microg of hemagglutinin per strain)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Intramuscular vaccination (0.25 ml of trivalent inactivated influenza vaccine, 7.5 microg of hemagglutinin per strain)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups (ID and IM)
Number of subjects: 126
Study: 17497710

Group type: EXPERIMENTAL
Intervention: Youth Eating Disorder Examination-Questionnaire (YEDE-Q)
Number of subjects: 35
Study: 15458016

Group type: EXPERIMENTAL
Intervention: PEEP
Number of subjects: 8

Group type: COMPARATOR
Intervention: No PEEP (Control)
Number of subjects: 8
Study: 11442735

Group type: EXPERIMENTAL
Intervention: Debridement group (supra‐ and subgingival ultrasonic instrumentation without analgesia)
Number of subjects: 105

Group type: COMPARATOR
Intervention: SRP group (scaling/root planing with local analgesia)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Debridement group
Number of subjects: 105

Group type: COMPARATOR
Intervention: SRP group
Number of subjects: 105
Study: 9512674

Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms/kg
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 593
Study: 8070610

Group type: EXPERIMENTAL
Intervention: Lisinopril (10-20 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Atenolol (50-100 mg/day)
Number of subjects: 35
Study: 31014947

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass surgery
Number of subjects: 2495

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2495

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 2495

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 2495

Group type: EXPERIMENTAL
Intervention: History of smoking
Number of subjects: 2495

Group type: EXPERIMENTAL
Intervention: Being single
Number of subjects: 2495

Group type: EXPERIMENTAL
Intervention: Being first-generation immigrant
Number of subjects: 2495

Group type: EXPERIMENTAL
Intervention: Elementary occupation
Number of subjects: 2495
Study: 27864832

Group type: EXPERIMENTAL
Intervention: Colistin (2.5 million IU intravenous dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 26105708

Group type: EXPERIMENTAL
Intervention: Post-release non-fatal overdose among PWID
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Post-release non-fatal overdose among all ex-prisoners
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Pre-release predictors of overdose among PWID
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Risky alcohol use in the year before prison
Number of subjects: 1051
Study: 23652464

Group type: EXPERIMENTAL
Intervention: Multifactorial non-pharmacological prevention program for hip fracture
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Multifactorial non-pharmacological prevention program
Number of subjects: 1004
Study: 21791965

Group type: EXPERIMENTAL
Intervention: hm gamma-PGA treatment in rats (NFP or HFP) for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: hm gamma-PGA supplementation (150 mg/day) in humans for 8 weeks
Number of subjects: 32
Study: 19332187

Group type: EXPERIMENTAL
Intervention: 6 months clopidogrel therapy after DES implantation
Number of subjects: 6000

Group type: COMPARATOR
Intervention: 12 months clopidogrel therapy after DES implantation
Number of subjects: 6000
Study: 16935786

Group type: EXPERIMENTAL
Intervention: Analytic accounting system of the hospital
Number of subjects: 0

Group type: COMPARATOR
Intervention: French Diagnosis Related Group (DRG) cost databases
Number of subjects: 0

Group type: COMPARATOR
Intervention: French DRG prospective payment system
Number of subjects: 0
Study: 15190231

Group type: EXPERIMENTAL
Intervention: SR 142801 (NK3 receptor antagonist)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SR 48692 (neurotensin receptor antagonist)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SR 141716 (cannabinoid receptor antagonist)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Levodopa (single dose)
Number of subjects: 24
Study: 10665517

Group type: EXPERIMENTAL
Intervention: Brinzolamide 0.3%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brinzolamide 2%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brinzolamide 3%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9305326

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BotB) 2,500 U
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BotB) 5,000 U
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BotB) 10,000 U
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 8313401

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 0
Study: 2871849

Group type: EXPERIMENTAL
Intervention: Atracurium (0.135-0.5 mg kg‐1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.02-0.1 mg kg‐1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Comparison of equipotent doses of atracurium and vecuronium
Number of subjects: 70
Study: 31210635

Group type: EXPERIMENTAL
Intervention: Sound therapy (maskers)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No sound therapy (control)
Number of subjects: 18
Study: 29538053

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 50
Study: 26540396

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Dexamethasone (female subgroup)
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Placebo (female subgroup)
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Dexamethasone and Placebo
Number of subjects: 1125
Study: 23832575

Group type: EXPERIMENTAL
Intervention: Bisphosphonate (Bis)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Calcitriol (VD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Menatetrenone (VK)
Number of subjects: 15
Study: 22711499

Group type: EXPERIMENTAL
Intervention: 238 g PEG + 1.9 L Gatorade
Number of subjects: 136

Group type: COMPARATOR
Intervention: 4 L of PEG-ELS
Number of subjects: 136
Study: 20472937

Group type: EXPERIMENTAL
Intervention: Lower oxygen saturation target range (85 to 89%)
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Higher oxygen saturation target range (91 to 95%)
Number of subjects: 1316
Study: 18721566

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) kallikrein inhibiting units (KIU) loading dose, 0.5 x 10(6) KIU/hour)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 120
Study: 16036509

Group type: EXPERIMENTAL
Intervention: Gluten challenge
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (non-coeliac subjects)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (classical coeliac disease patients)
Number of subjects: 41
Study: 11954952

Group type: EXPERIMENTAL
Intervention: Colforsin (0.5mg x kg(‐1) min(‐1) for 6 hours)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no colforsin treatment)
Number of subjects: 26
Study: 10623332

Group type: EXPERIMENTAL
Intervention: Nebuhaler pressurized metered dose inhaler (pMDI)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Turbuhaler dry powder inhaler
Number of subjects: 198
Study: 7494824

Group type: COMPARATOR
Intervention: Pure water (control solution)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mannitol 2.264 g/200 ml
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mannitol 10 g/200 ml
Number of subjects: 8
Study: 2188794

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid-rich fish oil (MaxEPA', 2.8 g EPA daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 10
Study: 7003448

Group type: EXPERIMENTAL
Intervention: 0.96 g single oral dose of co-trimoxazole
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1.92 g single oral dose of co-trimoxazole
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 2.88 g single oral dose of co-trimoxazole
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional five-day course of co-trimoxazole
Number of subjects: 64
Study: 31999147

Group type: EXPERIMENTAL
Intervention: Alcohol group (peak BAC of 0.07%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alcohol group
Number of subjects: 40
Study: 31358709

Group type: EXPERIMENTAL
Intervention: HyFlex™ EDM (HFEDM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: ProTaper Next (PTN)
Number of subjects: 22
Study: 28282504

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 27298538

Group type: EXPERIMENTAL
Intervention: Sub-mucosal injection of 0.5 mg/kg ketamine hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline infiltration (Placebo)
Number of subjects: 20
Study: 24632042

Group type: EXPERIMENTAL
Intervention: EG 500 (500 mg of encapsulated C. xanthocarpa)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: EG 1000 (1000 mg of encapsulated C. xanthocarpa)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control Group (CG, placebo treatment)
Number of subjects: 156
Study: 22853706

Group type: EXPERIMENTAL
Intervention: Branching case pathways present with structured clinical reasoning feedback present
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Branching case pathways present with structured clinical reasoning feedback absent
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Branching case pathways absent with structured clinical reasoning feedback present
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Branching case pathways absent with structured clinical reasoning feedback absent
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: One centre
Number of subjects: 112
Study: 19031070

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17298105

Group type: EXPERIMENTAL
Intervention: Desloratadine 5mg
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 15155114

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg subcutaneous daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study: 11369904

Group type: EXPERIMENTAL
Intervention: BCX-34 dermal cream 1%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vehicle cream (placebo)
Number of subjects: 90
Study: 9402450

Group type: EXPERIMENTAL
Intervention: Addition of felodipine to metoprolol
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Replacement of metoprolol by felodipine
Number of subjects: 363

Group type: COMPARATOR
Intervention: Continuation of metoprolol (control)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Felodipine monotherapy
Number of subjects: 363
Study: 8214490

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (0.027 mg)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Intravenous fentanyl (0.027 mg)
Number of subjects: 112
Study: 2884225

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nadolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28124444

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBT) combined with treatment-as-usual (TAU), weekly sessions for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 60
Study: 26850232

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL) using C-MAC device
Number of subjects: 198

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL) using C-MAC device
Number of subjects: 198
Study: 23826742

Group type: EXPERIMENTAL
Intervention: Finely ground maize (Fg) diet (0.5 mm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control diet (Ct) (1.0 mm)
Number of subjects: 12
Study: 22452928

Group type: EXPERIMENTAL
Intervention: Wood smoke exposure (14, 220, or 354 μg/m3 for 3 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Wood smoke exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 20
Study: 19758373

Group type: EXPERIMENTAL
Intervention: Anti-helminthic therapy
Number of subjects: 1566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1566
Study: 17701027

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 78
Study: 16223392

Group type: EXPERIMENTAL
Intervention: 2% lidocaine 2 ml with epinephrine (5 microg/ml)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 1% lidocaine 4 ml with epinephrine (2.5 microg/ml)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 1% lidocaine 4 ml with epinephrine (5 microg/ml)
Number of subjects: 108

Group type: COMPARATOR
Intervention: 1% lidocaine 4 ml (no epinephrine)
Number of subjects: 108
Study: 12139219

Group type: EXPERIMENTAL
Intervention: Dengue tetravalent live-attenuated vaccine (two doses, given six months apart)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 10557952

Group type: EXPERIMENTAL
Intervention: High-dose inhaled budesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard oral prednisone
Number of subjects: 0
Study: 8824656

Group type: EXPERIMENTAL
Intervention: 5‐ASA 1.5 g b.d.
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 2285294

Group type: EXPERIMENTAL
Intervention: 1 g of cephradine every 12 h for 7 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: 375 mg of amoxicillin‐clavulanate every 8 h for 7 days
Number of subjects: 88
Study: 7041936

Group type: EXPERIMENTAL
Intervention: Buprenorphine 1 mg + Paracetamol 1000 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Buprenorphine 1.5 mg + Paracetamol 1000 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg + Paracetamol 1000 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paracetamol 1000 mg alone
Number of subjects: 120